Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578247 · ClinicalTrials.gov registry record · Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
A Phase 3 study of Leukemia, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT06578247: Recruiting Phase 3 study of Leukemia, sponsored by Daiichi Sankyo.
NCT06578247 is a Phase 3 study of Leukemia that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 700 participants, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06578247, a Phase 3 study of Leukemia, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Primary Outcome
Overall survival (OS) is defined as the time from randomization until death from any cause.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Chemotherapy
- DRUG Quizartinib
Study Locations (20)
California
- David Geffen School of Medicine - Los Angeles
- University of California Davis Health System - Sacramento
- Ucsf - School of Medicine - San Francisco
- Stanford University School of Medicine- Parent - Stanford
Florida
- Mayo Clinic Hospital - Jacksonville
- Florida Hospital Cancer Institute - Kissimmee - Kissimmee
- Tampa General Hospital - Tampa
- Moffitt Cancer Center - Tampa
Arizona
- City of Hope Phoenix - Goodyear
- Mayo Clinic - Phoenix - Phoenix
- University of Arizona Cancer Center - Tucson
Illinois
- Robert H Lurie Comprehensive Cancer Center Northwestern University - Chicago
- University of Illinois Hospital & Health Sciences System - Chicago
- The University of Chicago Medical Center - Chicago
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Augusta University - Augusta
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale University - New Haven
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2030-06-26 |
| Phase | Phase 3 |
What NCT06578247 shows while recruiting
NCT06578247 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06578247 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06578247 about?
NCT06578247 is a clinical study titled "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML". This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
What is the current status of trial NCT06578247?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-11-19. Estimated completion is 2030-06-26.
What conditions does trial NCT06578247 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT06578247?
The interventions under investigation include: Placebo (DRUG), Chemotherapy (DRUG), Quizartinib (DRUG).
Who is sponsoring clinical trial NCT06578247?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06578247 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06578247's enrollment target sits among peer trials
700 13th of 233 higher than 220 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI